Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal

At the onset of this month, the UK and U.S. governments signed a landmark pharmaceuticals trade deal aimed at rebalancing transatlantic commerce and securing access to innovative medicines. The core of the agreement is a straightforward exchange — in return for the UK committing to pay more for U.S. drugs, the United States will exempt UK-origin pharmaceuticals from all import tariffs for at least three years.As this deal hikes drug prices substantially, U.S. pharma companies like Eli Lily (LLY) , Johnson & ...